Skip to main content

Advertisement

Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Fig. 3

Four-weekly RBV adherence among HCV genotype 2/3 participants on shortened (12 weeks; n = 61; panel a) and standard therapy (24 weeks; n = 26; panel b). Each row represents a study participant. Colours represent each participant’s RBV adherence during each four-week period with dark green representing 100% adherence and red representing 0% adherence. White represents discontinuation before completion of the corresponding time-point while black represents missing data for both retuned pill counts and patient reported adherence before treatment discontinuation

Back to article page